HGH Fragment 176-191 vs Adipotide
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Frag 176-191, HGH Frag
HGH Fragment 176-191 is exactly what it sounds like: a short tail-end piece of the human growth hormone molecule, amino acids 176 through 191. The idea was to keep the fat-burning part of growth hormone while ditching the parts that raise blood sugar and IGF-1. The bare fragment has never been tested in a controlled human trial. Its modified cousin, AOD-9604, did go through real obesity trials, and the blunt result is that it was very safe but did not produce meaningful weight loss. It is banned in sport by WADA.
Also: FTPP, Fat-Targeted Proapoptotic Peptide
Adipotide is an experimental peptide built to kill fat tissue by cutting off its blood supply. One half homes in on prohibitin, a protein on the blood vessels that feed white fat, and the other half is a cell-killing sequence that triggers those vessel cells to self-destruct. It produced striking weight loss in obese mice and monkeys, but it also caused kidney damage in every primate species tested, and its only human trial was terminated after enrolling 4 people with no results ever posted.
Key Comparison Insights
- Both peptides belong to the Weight Loss category, suggesting similar primary applications.
Detailed Comparison
| Attribute | HGH Fragment 176-191 | Adipotide |
|---|---|---|
| Category | Weight Loss | Weight Loss |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | This fragment is the C-terminal portion of growth hormone, the segment researchers linked to its effects on fat metabolism. The cleanest early data (Wu and Ng, 1993, rat fat tissue) found the closely related hGH 177-191 matched whole growth hormone at blocking new fat formation (antilipogenic) but had no significant direct fat-breakdown (lipolytic) effect. Later mouse work with AOD-9604 reported more fat oxidation, apparently without binding the growth hormone receptor itself. That is the selling point: because it does not act on the GH receptor, it does not raise IGF-1, does not promote tissue growth, and does not impair glucose handling the way full growth hormone can. Some research points to beta-3 adrenergic signaling in fat tissue, but the human mechanism is not nailed down. | The molecule has two parts joined together. The targeting part, CKGGRAKDC, was found by screening peptides in living mice for ones that stick to fat-tissue blood vessels; it binds prohibitin on the endothelial cells lining white fat vasculature. The payload, D(KLAKLAK)2, is a known pro-apoptotic peptide that disrupts mitochondrial membranes once inside a cell, setting off programmed cell death. Kill the vessels and the fat tissue they supply is starved and resorbed. This is a destructive mechanism, not a metabolic nudge like GLP-1 drugs, and that matters for safety: prohibitin is not exclusive to fat vessels, and the kidney's proximal tubule cells turned out to be a clear off-target casualty in monkeys. |
| Common Dosing | 250-500 mcg daily 1-2x daily, fasted | No established human dose Once daily in animal studies |
| Administration | Subcutaneous injection on empty stomach | Subcutaneous injection |
| Typical Duration | 8-12 weeks | 28 days in the main monkey efficacy study; up to 63 days in dose-escalation |
| Best Time to Take | Before bed or morning (fasted) | No evidence-based timing |
Possible Side Effects May vary by individual |
|
|
| Research Summary | The animal data looked promising and the human data deflated it, which is the whole story here. One caveat up front: every human result below comes from AOD-9604, the tyrosine-capped version, not the bare 176-191 fragment sold today. In obese mice (Endocrinology, 2001), both growth hormone and AOD-9604 reduced body-weight gain and increased fat oxidation, without the blood-sugar problems of full GH. A small 12-week phase 2 human study of AOD-9604 generated the early headline, with the 1 mg group losing modestly more weight than placebo. But the larger, better-powered phase 2b trial of roughly 500 obese adults over 24 weeks failed to show a significant weight-loss advantage over placebo, and the developer abandoned obesity development. What survived is the safety record: across about six trials and roughly 900 people, AOD-9604 was as well tolerated as placebo, with no IGF-1 rise and no glucose effects (Journal of Endocrinology and Metabolism, 2013). So the closest human data say safe, and not a meaningful fat-loss drug. | The concept came from Kolonin and colleagues (Nature Medicine, 2004), who reported that ablating fat vasculature reversed obesity in mice. The key primate study is Barnhart et al. (Science Translational Medicine, 2011) from MD Anderson. Obese rhesus monkeys given 0.43 mg/kg/day subcutaneously for 28 days lost 7.4% to 14.7% of body weight (average 10.6%) while controls stayed roughly flat, with MRI and DEXA confirming fat loss and clear improvements in insulin resistance. Lean monkeys at the same dose did not lose weight. The cost: serum creatinine rose in a dose-dependent way above 0.25 mg/kg, and the authors documented kidney tubule injury with glucose and protein in the urine, dehydration at higher doses, and low phosphorus and potassium. Most of it reversed within 28 days, but one treated monkey in each study still had residual changes. A first-in-human phase I trial at MD Anderson in obese men with metastatic prostate cancer (NCT01262664) started in 2012, enrolled only 4 patients, and was terminated at the investigator's request in 2019 with no results posted. That is the whole human record. Nobody knows the safe human dose, and the kidney signal is the opposite of reassuring. |
Frequently Asked Questions: HGH Fragment 176-191 vs Adipotide
What is the difference between HGH Fragment 176-191 and Adipotide?
HGH Fragment 176-191 is a weight loss peptide that hgh fragment 176-191 is exactly what it sounds like: a short tail-end piece of the human growth hormone molecule, amino acids 176 through 191. the idea was to keep the fat-burning part of growth hormone while ditching the parts that raise blood sugar and igf-1. the bare fragment has never been tested in a controlled human trial. its modified cousin, aod-9604, did go through real obesity trials, and the blunt result is that it was very safe but did not produce meaningful weight loss. it is banned in sport by wada. Adipotide is a weight loss peptide that adipotide is an experimental peptide built to kill fat tissue by cutting off its blood supply. one half homes in on prohibitin, a protein on the blood vessels that feed white fat, and the other half is a cell-killing sequence that triggers those vessel cells to self-destruct. it produced striking weight loss in obese mice and monkeys, but it also caused kidney damage in every primate species tested, and its only human trial was terminated after enrolling 4 people with no results ever posted. The main differences lie in their mechanisms of action and clinical applications.
Which is better, HGH Fragment 176-191 or Adipotide?
Neither is universally "better" - the choice depends on your specific goals. HGH Fragment 176-191 is typically used for weight loss purposes, while Adipotide is used for weight loss. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can HGH Fragment 176-191 and Adipotide be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using HGH Fragment 176-191 and Adipotide together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.